Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation-Reference-Cited by-同舟云学术

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Published:2013-07 Issue:13 Volume:23 Page:3741-3748
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Furet Pascal,Guagnano Vito,Fairhurst Robin A.,Imbach-Weese Patricia,Bruce Ian,Knapp Mark,Fritsch Christine,Blasco Francesca,Blanz Joachim,Aichholz Reiner,Hamon Jacques,Fabbro Doriano,Caravatti Giorgio

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference30 articles.

1. The Phosphoinositide 3-Kinase Pathway

2. Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer

3. Oncogenic PI3K and its role in cancer

4. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

5. The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway

Cited by 371 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Free energy landscape of the PI3Kα C-terminal activation;Computational and Structural Biotechnology Journal;2024-12

2. From lab to clinic: The discovery and optimization journey of PI3K inhibitors;European Journal of Medicinal Chemistry;2024-11

3. Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications;European Journal of Medicinal Chemistry;2024-10

4. MOLECULAR TARGETS AS POTENTIAL PI3Kα INHIBITORS AGAINST AGGRESSIVE METASTATIC DUCTAL AND LOBULAR CARCINOMA;International Journal of Applied Pharmaceutics;2024-09-07

5. PIK3CA-Related Disorders: From Disease Mechanism to Evidence-Based Treatments;Annual Review of Genomics and Human Genetics;2024-08-27